Compare Baxter International Inc (BAX) vs Boston Scientific Corporation (BSX) Price & Performance

Baxter International IncTrade

Boston Scientific CorporationTrade

Price performance (Past 24H)

Key statistics

Baxter International Inc vs Boston Scientific Corporation — how do they compare? Baxter International Inc trades at $27.61 (market cap $14.27B), while Boston Scientific Corporation trades at $51.15 (market cap $74.19B). The key difference: Boston Scientific Corporation is far larger — about 5.2× Baxter International Inc's market cap, and Baxter International Inc pays a 0.14% dividend while Boston Scientific Corporation pays none. Which is the better fit depends on your goals.

	BAX	BSX
Market Cap	$14.27B	$74.19B
Sector	Health	Health
52-Week High	$28.35	$108.14
52-Week Low	$15.80	$42.63
Enterprise Value	$21.79B	$86.27B
Dividend Yield	0.14%	—

View details →View details →

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

BAX

View details →

BSX

Boston Scientific posts strong Q2 growth despite U.S. challenges, stock now valued attractively.Seeking Alpha · 1 day agoBullish Boston Scientific to present at Wells Fargo Healthcare Conference and report Q3 2026 results in OctoberPRNewsWire · 2 days agoNeutral View details →

About Baxter International Inc

Baxter offers a variety of medical instruments and supplies to caregivers. It enhanced its portfolio of hospital-focused offerings by acquiring Hillrom in late 2021. Legacy Baxter offers tools to help patients with acute and chronic kidney failure. It also sells a variety of injectable therapies for use in care settings, such as IV pumps, and administrative sets.

About Boston Scientific Corporation

Boston Scientific produces less invasive medical devices that are inserted into the human body through small openings or cuts. It manufactures products for use in angioplasty, blood clot filtration, cardiac rhythm management, catheter-directed ultrasound imaging, structural heart disease, upper gastrointestinal tract diagnostics, interventional oncology, and treatment of incontinence. The firm markets its devices to healthcare professionals and institutions globally. Foreign sales account for nearly half of the firm's total sales.